NCT00316615View on ClinicalTrials.gov

Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2005

Conditions
Influenza Disease
Interventions
BIOLOGICAL

influenza vaccine

Trial Locations (2)

66100

G. D'Annunzio University, Chieti

Unknown

Office of Hygiene and Public Health, ASL Lanciano, Lanciano

Sponsors

Lead Sponsor

Novartis

Collaborators (1)

Novartis Vaccines
All Listed Sponsors
collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY

NCT00316615 - Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects. | Biotech Hunter | Biotech Hunter